Sound Bioventures

Founders Casper Breum and Johan Kördel lead the firm. The pair previously spent 15 years working together before launching Sound Bioventures, and the investment and portfolio-construction strategy is described as an expression of the lessons they learned during that prior collaboration. The broader team includes Ester Sklarsky, Anna Gran, Linda Spahiu Elvesjö, and Anne Marie Simon, though source material does not identify their exact decision-making structure beyond founder leadership.

The firm can lead, co-lead, or follow syndicates. It states that it almost always takes a board seat in portfolio companies and places particular emphasis on aligning its investment objectives with those of fellow investors. Regardless of role, Sound Bioventures always reserves capital for future rounds and will not invest in a company where it cannot maintain that follow-on capacity.

The firm invests in about-to-be clinical and clinical-stage private companies. It will participate in any private financing round, irrespective of Series label, provided the investment results in a clinical readout for the lead asset. Platform companies can be attractive if the lead asset reaches a clinical readout with the committed financing.

Medical devices, digital health, and diagnostics are explicitly out of scope. The firm also avoids what it judges to be incremental innovation or a pure-play regulatory or pricing story. All therapeutic modalities are in scope as long as the company is developing a novel medicine that addresses unmet medical need.